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Abstract
Objectives: Growing evidence supports the role of the intestinal microbiome in the carcinogenesis of colorectal
cancers, but its impact on colorectal cancer surgery outcomes is not clearly defined. This systematic review aimed
to analyze the association between intestinal microbiome composition and postoperative complication and survival
following colorectal cancer surgery.
Methods: A systematic review was conducted according to the 2009 PRISMA guidelines. Two independent
reviewers searched the literature in a systematic manner through online databases, including Medline, Scopus,
Embase, Cochrane Oral Health Group Specialized Register, ProQuest Dissertations and Theses Database, and Google
Scholar. Human studies investigating the association between the intestinal microbiome and the short-term
(anastomotic leakage, surgical site infection, postoperative ileus) and long-term outcomes (cancer-specific mortality,
overall and disease-free survival) of colorectal cancer surgery were selected. Patients with any stage of colorectal
cancer were included. The Newcastle-Ottawa scale for case-control and cohort studies was used for the quality
assessment of the selected articles.
Results: Overall, 8 studies (7 cohort studies and 1 case-control) published between 2014 and 2018 were included.
Only one study focused on short-term surgical outcomes, showing that anastomotic leakage is associated with low
microbial diversity and abundance of Lachnospiraceae and Bacteroidaceae families in the non-cancerous resection
lines of the stapled anastomoses of colorectal cancer patients. The other 7 studies focused on long-term
oncological outcomes, including survival and cancer recurrence. The majority of the studies (5/8) found that a
higher level of Fusobacterium nucleatum adherent to the tumor tissue is associated with worse oncological
outcomes, in particular, increased cancer-specific mortality, decreased median and overall survival, disease-free and
cancer-specific survival rates. Also a high abundance of Bacteroides fragilis was found to be linked to worse
outcomes, whereas the relative abundance of the Prevotella-co-abundance group (CAG), the Bacteroides CAG, and
the pathogen CAG as well as Faecalibacterium prausnitzii appeared to be associated with better survival.
Conclusions: Based on the limited available evidence, microbiome composition may be associated with colorectal
cancer surgery outcomes. Further studies are needed to elucidate the role of the intestinal microbiome as a
prognostic factor in colorectal cancer surgery and its possible clinical implications.
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Background
In recent years, several studies have shown the impact of
the intestinal microbiome on host health and disease de-
velopment. The human intestinal microbiome is a com-
plex community of bacteria, archaea, viruses, and
eukaryotes that is subject-specific and stable in healthy
individuals [1]. Disturbances in the balance of the com-
position and function of the microbiome are associated
with the onset of various pathologies, including obesity,
Crohn’s disease, and gastrointestinal malignancies [2].
Indeed, a growing amount of evidence supports the role
of the microbiome as a risk factor for the carcinogenesis
of several malignancies, including colorectal cancers [3].
Conversely, the impact of the microbiome on the occur-
rence of postoperative complications and on the devel-
opment of local recurrence after colorectal cancer
surgery is not clearly defined.
Assessing whether the microbiome is a potential risk
factor for postoperative complications of colorectal sur-
geries could lead to modifying perioperative care, as
multiple perioperative interventions, such as mechanical
bowel preparation (MBP) and antibacterial therapy
(ABT), drastically influence microbiome composition,
especially bacterial diversity [4, 5]. MBP, with or without
ABT, is widely but empirically implemented before colo-
rectal surgery to carry out a “clean” intervention that
minimizes the risk of fecal contamination of the opera-
tive field, particularly during the anastomosis prepar-
ation. However, it has been shown that the loss of
bacterial diversity could be a risk factor for postoperative
complications, questioning the role of preoperative MBP
and ABT [4].
Studies of animal models have shown that a eubiotic
state is important for normal wound healing, including
anastomosis repair after colorectal surgery [6]. Bacterial
competition and cooperation can either promote or
hamper wound healing during the inflammatory phase,
influencing cellular activation and fibrosis in the wound
repair process [5]. In the eubiotic state, bacteria remain
harmless and do not cause infections, whereas following
changes in the local environment and the induction of
dysbiosis, by surgical injury for example, bacterial inva-
sion and tissue inflammation take place [7].
Due to the major role of the microbiome in inflamma-
tion and wound healing [8], it is plausible that dysbiosis
may be related to the development of colorectal surgery
complications, such as anastomotic leakage (AL), surgi-
cal site infections (SSI), and prolonged postoperative
ileus (PPI) [9, 10].
The composition of the intestinal microbiome may
also impact the long-term outcomes of surgical treat-
ments of colorectal cancer. Local recurrences of colorec-
tal cancer are reported in 1–23% of cases after curative
surgery [11]; this rate varies depending on tumor stage,
localization, neoadjuvant and adjuvant therapies, and
surgical technique [12]. Moreover, the occurrence of
major postoperative complications has been related to
worse oncological outcomes and overall and disease-free
survival [13]. Of note, regarding the occurrence of post-
operative complications, the administration of adjuvant
chemotherapy may be delayed or contraindicated due to
an insufficient patient performance status, which im-
pacts prognosis [14].
In this context, it would be important to characterize
the intestinal microbiome not only as a potential con-
tributor to early postoperative complications (e.g., AL)
but also as a potential marker of cellular and molecular
mechanisms linked to local recurrence.
The present systematic review aims to analyze the
available literature about the intestinal microbiome and
its association with postoperative complications and
long-term oncological outcomes after colorectal cancer
surgery. To our knowledge, there is no existing review
on the topic that has been performed with a systematic
approach.
Materials and methods
Data sources and search strategy
A systematic review was performed following the
Cochrane collaboration-specific protocol [15] and was
reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
statement.
Studies that investigated the association between the
intestinal microbiome and surgical outcomes/postopera-
tive complications and/or oncological outcomes/survival
in colorectal cancer patients were searched in the
following databases without date restrictions: Medline
(through PubMed), Scopus, Embase, Cochrane Oral
Health Group Specialized Register, ProQuest Disserta-
tions and Theses Database, and Google Scholar. A
specific research equation was used for each database,
using the following keywords and MeSH terms: micro-
biome, microbiota, colorectal, surgery, surgical proce-
dures, operative surgical procedures, general surgery,
complications, anastomotic leak, surgical wound infec-
tion, surgical site infection(s), ileus, recurrence, mortal-
ity, survival, outcomes.
According to the PICOS schema, the following criteria
were used for the literature search and selection:
P, population: adult patients with colorectal cancer who
underwent surgical resection. Any stage of colorectal
cancer (according to the AJCC classification) was
considered [16].
I, intervention: analysis of the luminal or mucosa-
associated microbiome from fecal samples or colorectal
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tissues. Both culture-dependent and genome sequen-
cing methods were considered.
C, comparisons: patients with and without
postoperative complications and patients with different
bacterial DNA loads in their microbiome samples.
O, outcome(s): postoperative complications 90 days
after surgery, including AL, SSI, and PI. Long-term out-
comes comprised overall survival (OS), cancer-specific
survival (CSS), disease-free survival (DFS), and
recurrence-free survival (RFS).
S, study design: randomized and non-randomized clin-
ical trials, including cohort and case-control studies.
Studies that investigated colorectal diseases other than
cancer, evaluating the impact of probiotic treatments, or
focusing exclusively on the pathogenesis of colorectal
cancer were not eligible for inclusion. The search was
limited to human studies published in English. Then, the
literature review was completed by using the “related ar-
ticles” function in PubMed, to ensure an extensive ap-
proach. Moreover, the reference lists of the eligible
records and pertinent review articles that were not in-
cluded in this study were double-checked to identify po-
tential additional articles for inclusion.
The literature search and selection were performed by
two independent reviewers (LL and ER). Records were
removed from the selection if both reviewers excluded
the articles at the title/abstract screening levels. Dis-
agreement was resolved via a discussion with a third re-
viewer (NdeA). Overall, the concordance rate between
the two reviewers was 95%.
Details of the study protocol are registered in the
International prospective register of systematic reviews,
PROSPERO (ID number CRD42019117597).
Data extraction
Both reviewers performed an independent full-text ana-
lysis and data extraction by filling in an electronic
database. Extracted data included the first author’s
name, year of publication, number of patients, type of
microbiome, type of postoperative complications (AL,
SSI, PPI), and oncological outcomes (recurrence, OS,
DFS). Characterization of both the luminal microbiome
(LM, fecal microbiome) and the mucosa-associated
microbiome (MAM) was considered and described [17].
AL is defined as a defect in the bowel wall at the anas-
tomotic site (including suture and staple lines of neorec-
tal reservoirs) leading to communication between the
intraluminal and extraluminal compartments [18].
SSI refers to an infection that develops 30 days after
the surgery (or 1 year after the surgery if an implant has
been placed) and is classified as superficial incisional
SSI, deep incisional SSI, and organ/space SSI [19].
PPI is generally characterized by the presence of nau-
sea and vomiting, inability to tolerate oral dietary intake,
abdominal distension, and delayed passage of flatus and
stool during the postoperative period [20].
Study quality assessment and risk of bias
Two reviewers (LL and ER) carried out the study quality
assessment and risk of bias evaluation of the selected
articles. According to the study design, the New Castle–
Ottawa scale (NOS) was used [21].
Results
Literature search and selection
The initial search yielded 383 results; after removing du-
plicates, 382 articles were screened for eligibility based
on title and abstract, and 21 articles were retrieved for a
full-text evaluation. A total of 8 studies fulfilled the in-
clusion criteria and were finally included in the review
[22–29] (Fig. 1). The excluded articles and detailed
reasons for exclusion are reported in Additional file 1:
Table S1.
Study characteristics
The selected studies were published between 2014 and
2018, and there were 7 cohort studies [22–28] and 1
case-control [29]. The studies were carried out in
Europe (n = 3), North America (n = 2), and Asia Pacific
(n = 3). The general characteristics of the studies exam-
ined are summarized in Table 1. The overall total num-
ber of patients considered is 3263.
Of the 8 selected articles, only one analyzed short-
term outcomes, more specifically, the rate of AL [29].
No data were reported concerning SSI or PI. The other
7 articles focused on oncological long-term outcomes,
that is, overall survival, mortality, and recurrence.
All of the included studies used microbial DNA
analysis as a method for microbiome detection and
characterization. Three articles studied the general com-
position of the microbiome in the sample, while 5 others
looked for a particular bacterium, as shown in Table 1.
In the first three studies [23, 26, 29], culture-
independent profiling of bacterial communities in tissue
samples was performed using amplification of bacterial
16S ribosomal RNS gene (16S rRNS). While Flemer
et al. [23] and Praagh et al. [29] targeted variable regions
V3 and V4 of the gene, Wei et al. [26] sequenced only
V4 region. In the studies of Wei et al. and Praagh et al.,
statistical analysis was performed on the family, genus,
and species level, whereas Flemer et al. did genus-based
analysis. Rest of the studies [22, 24, 25, 27, 28] focused
on detection of specific bacterial genus—Bifidobacterium
[24]—or species—Fusobacterium nucleatum (Fn) [22, 25,
27, 28]. DNA detection and bacteria quantification were
performed by real-time quantitative PCR (qPCR) method
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targeting 16S rRNA gene DNA sequence of Bifidobacter-
ium and different Fn genes (16 s rRNA gene, nusG
gene). In all studies but one [29], differences in micro-
biome composition were analyzed according to tumor
stage. The main results of the selected studies are sum-
marized in Table 2.
Microbiome and short-term outcomes
Only one study published by van Praagh et al. investi-
gated the relationship between a short-term surgical
outcome, namely AL, and the composition of the intes-
tinal microbiome [29]. The article reports a secondary
analysis of data obtained from a previously published
study [30] and investigates the association of intestinal
microbiome with the development of colorectal AL de-
pending on treatment method. The authors analyzed AL
that required reintervention in patients who underwent
colorectal surgery with or without the placement of a C-
seal, a bioresorbable sheath stapled to the anastomosis.
The mucosa-associated microbiome was analyzed from
the stapled colorectal “donut.” The results of this study
showed that in the patient group without the C-seal, AL
was significantly associated with a lower biodiversity of
the microbiome and a higher abundance of the mucin-
degrading microbiome families Lachnospiraceae and
Bacteroidaceae compared with matched patients who
did not develop AL. Conversely, in the patient group re-
ceiving the C-seal, who showed a slightly higher rate of
AL than the non-C-seal group, no association between
AL and microbiome composition was detected. Only a
few opportunistic pathogenic groups with a low abun-
dance were associated with AL, particularly Prevotella
oralis. The authors concluded that in patients who
underwent colorectal surgery without C-seal placement,
Fig. 1 PRISMA flow diagram for study search, selection, inclusion, and exclusion. Example or search terms strategy: (("microbiota"[MeSH Terms] OR
"microbiota"[All Fields] OR "microbiome"[All Fields]) AND colorectal[All Fields]) AND (("surgery"[Subheading] OR "surgery"[All Fields] OR "surgical
procedures, operative"[MeSH Terms] OR ("surgical"[All Fields] AND "procedures"[All Fields] AND "operative"[All Fields]) OR "operative surgical
procedures"[All Fields] OR "surgery"[All Fields] OR "general surgery"[MeSH Terms] OR ("general"[All Fields] AND "surgery"[All Fields]) OR "general
surgery"[All Fields]) OR ("complications"[Subheading] OR "complications"[All Fields]) OR ("anastomotic leak"[MeSH Terms] OR ("anastomotic"[All
Fields] AND "leak"[All Fields]) OR "anastomotic leak"[All Fields]) OR ("surgical wound infection"[MeSH Terms] OR ("surgical"[All Fields] AND
"wound"[All Fields] AND "infection"[All Fields]) OR "surgical wound infection"[All Fields]) OR ("ileus"[MeSH Terms] OR "ileus"[All Fields]) OR
("recurrence"[MeSH Terms] OR "recurrence"[All Fields]) OR ("mortality"[Subheading] OR "mortality"[All Fields] OR "mortality"[MeSH Terms]) OR
("mortality"[Subheading] OR "mortality"[All Fields] OR "survival"[All Fields] OR "survival"[MeSH Terms]) OR outcomes[All Fields])
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Table 1 Characteristics of the included studies
Authors,
year
Study
design
No. of
patients1
Tumor
stage
Microbiome
type, tissue
sample
Detection
method
Bacteria2 Short-term
surgical
outcomes
Long-term
oncological
outcomes
Mean
(SD) or
median
(range)
follow-
up
Adjustments on
covariates
Flanagan
et al.,
2014
Cohort 32 Dukes
staging
A-D
MAM, tumor Bacterial
DNA,
qPCR
Fusobacterium
nucleatum
Not reported • Overall
survival
5 years Not specified
Flemer
et al.,
2018
Cohort 47 AJCC
I-IV
MAM, tumor Bacterial
DNA, V3-
V4 16S
rRNA
CAG Not reported • Overall
survival
1371
days
(67–
1792
days)
Tumor stage, age,
gender, treatment
with chemotherapy
and/or radiotherapy
and cancer site
Kosumi
et al.,
2018
Cohort 1313 AJCC
I-IV
MAM, tumor Bacterial
DNA,
qPCR
Bifidobacterium Not reported • Cancer-
specific
mortality
• Overall
mortality
14.3
years
(10–
18.3
years)
Microsatellite instability
status, CpG island
methylator phenotype,
long-interspersed nu-
cleotide element-1
methylation, KRAS,
BRAF, and PIK3CA
mutations.
Mima
et al.,
2016
Cohort 1069 AJCC
I-IV
MAM, tumor Bacterial
DNA,
qPCR
Fusobacterium
nucleatum
Not reported • Cancer-
specific
mortality
• Overall
mortality
10.7
years
(7–15.8
years)
Age, sex, year of
diagnosis, family
history of colorectal
carcinoma in a first-
degree relative, tumor
location, microsatellite
instability (MSI, mis-
match repair defi-
ciency), CpG island
methylator phenotype
(CIMP), KRAS, BRAF,
and PIK3CA mutations,
and LINE-1 hypome-
thylation (low-level
methylation).
Van
Praagh
et al.,
2017
Case-
control
118 Not
specified3
MAM,
anastomosis
Bacterial
DNA, V3-
V4 16S
rRNA
All Anastomotic
leakage
Not reported Not
reported
Not specified
Wei et al.,
2016
Cohort 180 AJCC
I-IV
MAM, tumor Bacterial
DNA, V4
16S rRNA
All Not reported • Overall
survival
• Disease-
free
survival
47
months
(36–59
months)
Not specified
Yan et al.,
2017
Cohort 208 AJCC
III-IV
MAM, tumor Bacterial
DNA,
qPCR
Fusobacterium
nucleatum
Not reported • Cancer-
specific
survival
• Disease-
free
survival
Not
reported
Not specified
Yu et al.,
2017
Cohort 296 AJCC
II-III
MAM, tumor Bacterial
DNA,
qPCR
Fusobacterium
nucleatum
Not reported •
Recurrence-
free
survival
Not
reported
Not specified
AJCC, American Joint Committee on Cancer; MAM, mucosa-associated microbiome; CAG, tissue-associated microbial co-abundance groups; qPCR, quantitative
polymerase chain reaction
1Patients included in the analysis of the microbiome and its association with short- or long-term outcomes
2Bacteria analyzed for an association with short- or long-term outcomes
3The study also included 6 non-oncological patients
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Table 2 Summary of the main results of the included studies
Authors,
year
Bacteria1 Bacterial characteristics in
tissues
Association between microbiota
composition and tumor stage
Results
Short-term outcomes
Van
Praagh
et al.,
2017
Lachnospiraceae
Bacteroidaceae
High abundance +
Low microbial diversity in
patients with or without C-
seal
Not reported - AL patients without a C-seal showed a signifi
cant lower microbial diversity, more Bacter
oides, more Lachnospiraceae, and less Prevotella
and Streptococci than C-seal patients who
developed AL.
- AL cases of non-C-seal patients seem to be
almost without exception dominated by
Lachnospiraceae and Bacteroidaceae with
correspondingly low microbial diversity scores
- Relation between the composition of the
intestinal microbiota and the subsequent
development of AL after stapled colorectal
anastomoses, but only in patients who
underwent surgery without the additional
C-seal that covered the anastomoses
Long-term outcomes
Flanagan
et al.,
2014
F. nucleatum High vs. low or fold increase
from normal
No significant differences
between patients with no/low
or high F. nucleatum, in TNM/
Dukes staging.
- A significant difference in survival between
patients without detected F. nucleatum in
tumor tissue or low fold increase vs. those
with high fold increase.
- Median survival of subjects with high F.
nucleatum fold increase is 2 years, whereas all
subjects with low tumor to normal ratio
survive more than 3 years (HR = 19.96, 95%
CI = 1.42–281.42, p = 0.0266).
Flemer
et al.,
2018
Pathogen CAG
Prevotella CAG
Bacteroides CAG
Firmicutes CAG
Relative abundance Not specified - Pathogen CAG-type microbiota was associated
with longer survival (HR = 0.8, CI = 0.6–1.06;
p = 0.12)
- Prevotella CAG-type microbiota was associated
with longer survival (HR = 0.36, CI = 0.12–1.1;
p = 0.075).
- Bacteroidetes CAG was associated with longer
survival (HR = 0.75, CI = 0.58–1.03; p = 0.078).
- Firmicutes CAG 2 was associated with shorter
survival (HR = 1.52, CI = 0.84–2.75; p = 0.17)
Kosumi
et al.,
2018
Bifidobacterium Negative vs. low vs. high
DNA weight
Difference in Bifidobacteria
was not associated with disease
stage
No significant associations of the amount of
Bifidobacteria with colorectal cancer-specific
mortality or overall mortality
Mima
et al.,
2016
F. nucleatum High vs. low vs. negative
DNA load
The amount of tissue
F. NUCLEATUM DNA was
associated with higher pT
stage (p = 0.0007). The
association was not statistically
significant with pN or M stage.
- Compared with F. nucleatum-negative cases, F.
nucleatum-high cases had an HR = 1.58 (95%
CI = 1.04–2.39) for cancer-specific mortality
- A higher amount of tissue F. nucleatum DNA
was associated with shorter colorectal cancer-
specific survival (p = 0.023) but no difference
in overall mortality rate
Wei et al.,
2016
B. fragilis
F. nucleatum
F. prausnitzii
High vs. low abundance - High abundance of F. nucleatum
was significantly correlated with
positive lymph node metastasis
- High abundance of F. prausnitzii
and F. nucleatum was significantly
correlated with worse depth of
invasion
- Higher level of B. fragilis (9.75% vs. 2.62%, FDR
= 0.017) in non-survival group than in survival
group,
- F. prausnitzii (2.96% vs. 0.92%, FDR = 0.028)
and Methylobacterium suomiense (1.91% vs.
0.78%, FDR = 0.098) were more abundant
in the survival group.
- F. nucleatum was higher in non-survival group
than survival group (5.66% vs. 1.08%, FDR
= 0.076) and it exhibited a greater abundance
in the recurrence group than in survival group
(5.10% vs. 1.08%, FDR = 0.08)
- B. fragilis and F. prausnitzii might be correlated
with patient’s survival in CRC
- 3-year OS was significantly lower in patients
with high B. fragilis and F. nucleatum than in
those with low abundance of these two
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a bacterial composition of the intestinal microbiome
consisting of 60% or more Lachnospiraceae and Bacter-
oidaceae is a predictive factor for AL. The lack of this
association in C-seal patients may be explained by the
effect of C-seal placement, which creates a new ecosys-
tem that consequently influences and alters the compos-
ition of the resident microbiome [29]. Although the
largest proportion of patients had colorectal cancer, it is
worth noting that 3 patients in each group underwent
surgery for non-oncological colorectal diseases.
Microbiome and long-term outcomes
High heterogeneity was found in terms of considered
outcomes and detected bacteria in studies evaluating
long-term outcomes of colorectal cancer surgery in rela-
tion to intestinal microbiome.
The bacterium most frequently studied in cancer sam-
ples is Fusobacterium nucleatum [22, 25–28] (F. nuclea-
tum). Studies have shown that F. nucleatum abundance
increases as the disease progresses from an adenoma to
cancer [22]. Levels of F. nucleatum are found to be
higher in higher pT stages of cancer [25]. However, a
study by Flanagan et al. found discordant results show-
ing no differences between F. nucleatum levels and
tumor stage or mutation status of KRAS and BRAF [22].
All studies investigating the role of F. nucleatum con-
firmed that higher levels of F. nucleatum in tumor sam-
ples correlated with worse outcomes in terms of OS,
DFS, or cancer-specific survival [22, 25–28], with hazard
ratios ranging from 1.58 to 19.96 (Table 2). An unfavor-
able prognosis could also be linked to the fact that F.
nucleatum helps to activate autophagy-related pathways
in colorectal cancer patients, promoting chemoresistance
to oxaliplatin and 5-FU [28].
One study investigated the concentrations of Bifido-
bacterium, whose presence in tumor samples has been
linked to the presence of signet ring cells [24]. In this
study, Kosumi et al. reported that Bifidoacterium was
Table 2 Summary of the main results of the included studies (Continued)
Authors,
year
Bacteria1 Bacterial characteristics in
tissues
Association between microbiota
composition and tumor stage
Results
microbiota (p = 0.001, p = 0.003).
- Low abundance of F. prausnitzii showed
worse 3-year OS, (p = 0.06).
- B. fragilis (HR = 2.01; 95% CI = 1.02–3.96;
p = 0.044) and F. nucleatum (HR = 1.99; 95%
CI = 1.02–3.87; p = 0.042) were independent
predictor of the 3-year OS
- B. fragilis (HR = 2.04; 95% CI = 1.11–3.73;
p = 0.021) and F. nucleatum (HR = 1.82; 95%
CI = 1–3.34; p = 0.05) were associated with
poor 3-year DFS both
Yan et al.,
2017
F. nucleatum High vs. low level - In both stage III and IV tumor,
F. nucleatum level was
significantly higher in CRC
tissues than in adjacent normal
tissues
- F. nucleatum was found to
significantly associated with tumor
invasion (p = 0.015), LNM status
(p = 0.008), and distant metastasis
(p = 0.020).
- Stage IIIA patients with low F.
nucleatum level had no better
CSS and DFS than those with
high F. nucleatum level
- High F. nucleatum level was
significantly associated with
worse CSS and DFS in stage IIIB
and IV patients
- Patients with high F. nucleatum level had a
significantly worse CSS and DFS than those
with low F. nucleatum level
For CSS: HR = 2.22; 95% CI = 1.48–3.32;
p < 0.001
For DFS: HR = 2.0; 95% CI = 1.39–2.86;
p < 0.001
Yu et al.,
2017
F. nucleatum High vs. low amount The amount of F. nucleatum was
positively associated with the AJCC
stage and tumor size
- The 5-year RFS was substantially shorter in
the F. nucleatum-high group than the F.
nucleatum-low group.
- F. nucleatum was an independent predictor
of CRC aggressiveness with significant HR
for predicting clinical outcome. Its predictive
value was comparable with that of the AJCC
stage
AL, anastomotic leakage; CAG, tissue-associated microbial co-abundance groups; CRC, colorectal cancer; HR, hazard ratios; OS, overall survival; CSS, cancer-specific
survival; DFS, disease-free survival; RFS, recurrence-free survival; NS, not stated in the manuscript; LNM, lymph node metastasis
1Bacteria specifically associated with analyzed outcome
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found in 30% of the tumor samples, but no statistically
significant correlation was noted in terms of the immune
response or in the survival analysis (considering both
cancer-specific survival and overall mortality).
Another study investigated the co-abundance groups
(CAGs) of different bacteria [23]. The Prevotella CAG,
pathogen CAG, and Bacteroidetes CAG were associated
with improved survival. Although the presence of these
specific CAGs has been linked to inflammatory response
activation and high levels of Prevotella, pathogen CAGs
were shown to positively influence cancer-related sur-
vival. Other bacteria, such as Faecalibacterium prausnit-
zii, were correlated with a better survival outcome [26].
Study quality assessment
Based on the Newcastle-Ottawa Quality assessment scale
(NOS), one study received 8/9 stars, three studies re-
ceived 6/9, three studies received 5/9, and one study re-
ceived 4/9. The details are displayed in Additional file 1
Table S2. It must be stressed that a high heterogeneity
in the study designs, study populations, analyzed micro-
biomes, and outcomes was observed. All included stud-
ies were retrospective cohort or case-control studies.
Discussion
The present systematic review is the first, to our know-
ledge, to analyze the existing literature about the intes-
tinal microbiome and its association with short- and
long-term outcomes after colorectal cancer surgery in a
systematic manner.
Literature about the impact of microbiome diversity
on the occurrence of postoperative complications after
colorectal cancer surgery is very limited. Only one study
focused on the relationship between the composition of
the microbiome and AL [29] and showed that a low mi-
crobial diversity and high abundances of Lachnospira-
ceae and Bacteroidaceae were significantly related to AL.
These findings were used for a predictive analysis, which
revealed that samples with a total sum of Lachnospira-
ceae and Bacteroidaceae higher than 60% and a Simpson
diversity score on the family level < 0.75 are prone to de-
veloping AL, with an odds ratio of 28 (95% confidence
interval not reported). Interestingly, both bacterial fam-
ilies are normal habitants of the intestinal microbiome
and are important for the healthy functioning of the co-
lonic epithelium, with Faecalibacterium prausnitzii and
Eubacterium rectale (Lachnospiraceae family) being the
two most common species in the human gut [31]. The
Lachnospiraceae family is rich in butyrate-producing
bacteria that provide a crucial energy source for colon
epithelial cells that is essential for the maintenance of
gut barrier functions and immunomodulatory and anti-
inflammatory properties. To explain the findings with
possible pathophysiological effects, it would be crucial to
compare the composition of the microbiome before and
after surgery.
Half of the included studies focused on F. nucleatum
and its association with the long-term oncological out-
comes of colorectal cancer patients. All studies showed
that high concentrations of F. nucleatum had a negative
impact on survival outcomes and were associated with
decreased OS [26], decreased median survival [22], de-
creased CSS [27], decreased DFS [26, 27], decreased RFS
[28], and increased cancer-specific mortality [25]. How-
ever, we must be careful in interpreting these results be-
cause the available data rarely or only partially
considered the many potential confounding factors that
can influence survival outcomes.
In recent years, multiple reviews have analyzed the re-
lationship between Fusobacteria and colorectal cancer.
Several studies that detected a higher abundance of F.
nucleatum in colorectal adenomas compared with
healthy colorectal tissues [32] suggested the possible in-
volvement of this bacterium in the pathogenesis of colo-
rectal cancer. A study by Flanagan et al. [22] supports
this hypothesis, indicating that not only there are higher
F. nucleatum levels in individuals with adenomas than in
controls but also that F. nucleatum levels increase
through adenomatous stage progression from a tubular
adenoma to a high-grade dysplasia and colorectal cancer.
Indeed, F. nucleatum is able to invade human epithelial
cells, activate the β-catenin pathway, and trigger onco-
genic gene expression using the FadA adhesion virulence
factor; consequently, it can stimulate colorectal cancer
cell growth [33]. Moreover, a high abundance of F.
nucleatum is associated with cancer progression and
lymph node metastases, as shown in the study by Li
et al. [34]. The majority of the included studies [25–28]
also found a significant association of F. nucleatum with
one or more unfavorable cancer characteristics—ad-
vanced stage, tumor invasion, lymph node metastasis,
and tumor size. Further important evidence was ob-
tained from the study by Yu et al. [28], which
highlighted the negative impact of F. nucleatum on
oncological outcomes. This study compared microbiome
composition between recurrent and non-recurrent colo-
rectal cancers and found that F. nucleatum is the most
enriched bacterium in recurrent cases. Moreover, the
study suggests that F. nucleatum may promote resist-
ance to oxaliplatin and 5-FU chemotherapy regimens via
the colorectal cancer cell autophagy pathway, therefore
leading to decreased recurrence-free survival.
Another bacterium that was found to be associated
with unfavorable oncological outcomes was B. fragilis, as
shown in the study by Wei et al. [26]. Like F. nucleatum,
B. fragilis was also associated with decreased 3-year OS
and DFS. However, unlike F. nucleatum, which is an in-
digenous species in the oral cavity and is associated with
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only pathological changes in the colon and rectum, B. fra-
gilis is present in the intestinal microbiome of all healthy
individuals. In particular, enterotoxigenic B. fragilis
(ETBF) has been linked to the development of colorectal
cancer. Purcell et al. [35] showed an increased abundance
of ETBF in early stage carcinogenic lesions—low-grade
dysplasia and tubular adenomas. Viljoen et al. [36] de-
scribed significantly higher ETBF and F. nucleatum levels
in individuals with advanced stage III and IV colorectal
cancer. Therefore, it remains to be determined whether
the worse oncological outcomes described by Wei et al.
[26] are due to specific pathways in carcinogenesis or the
B. fragilis association with advanced cancer stages.
Kosumi et al. [24] analyzed the relationship between
the Bifidobacterium genus and colorectal cancer charac-
teristics and outcomes. Bifidobacterium has been of
interest in many studies, mainly concerning probiotic
administration and their effect on gastrointestinal and
extra-digestive pathologies. Bifidobacteria are normal
habitants of the intestinal tract and are present from an
early age. The imbalance of Bifidobacteria has been as-
sociated with several non-oncological diseases [37], but
few studies have suggested its association with colorectal
cancer. Indeed, it has been shown that there are de-
creased levels of Bifidobacteria in patients with colorec-
tal cancer compared with the levels in controls or
patients with diverticular disease [38]. Conversely,
Kosumi et al. [24] did not find any significant association
between the amount of Bifidobacteria and cancer-
specific and overall mortality or any relationship with
the clinical, pathological, or molecular characteristics of
colorectal cancer. Despite the paucity of literature, it is
likely that Bifidobacteria exert a beneficial effect during
the early stages of carcinogenesis, acting as a prebiotic
agent in improving epithelial defenses against infections
[39]. The study by Flemer et al. [23] is the only one that
focused on the analysis and comparison of tissue-
associated groups of various bacteria rather than individ-
ual bacteria. In their previous work [40], the authors de-
fined 6 mucosa-associated bacterial co-abundance
groups (CAGs) and showed an increased abundance of
the Firmicutes CAG 2, the Prevotella CAG, the pathogen
CAG, and the Bacteroidetes CAG 2 in tissues of colorec-
tal cancer compared with their levels in tissues of con-
trol subjects. Moreover, they showed that the pathogen
CAG and the Prevotella CAG were correlated and that
their gene expression levels were previously associated
with decreased survival in patients with colorectal can-
cer. In the most recent study, the results support the
idea that the two latter CAGs are in fact associated with
longer survival [23]. The authors stressed the import-
ance of further studies to explain this outcome.
The present systematic review is based on 8 original
studies with variable quality and risk of bias
characterized by a high degree of heterogeneity in terms
of study design, sample size, patient population, clinical
characteristics, bacterial sampling and detection
methods, target microbiome, and target outcome. Al-
though all studies that focused on oncological outcomes
detected MAM from tumor samples and in 5 of these
studies [22, 25–28], they analyzed a DNA load of F.
nucleatum, it must be stressed that each study used dif-
ferent types of samples. Only Flanagan et al. and Wei
et al. used fresh frozen tissue samples as opposed to
formalin-fixed paraffin-embedded (FFPE) samples used
in the rest of the studies. It has been shown previously
that FFPE specimens have lower expression of the ana-
lyzed targets than fresh frozen samples, which is of great
importance in the quantitative analysis of bacteria [41].
Three studies [22, 23, 27] analyzed the microbiome in
healthy tissues from the same patient as a reference. Al-
though this approach is a common practice in studies
focusing on microbiome detection in colorectal cancer
and is used to exclude interindividual microbiome differ-
ences, there is contradictory evidence whether the
healthy and cancerous tissues from the same subject are
representative of healthy and cancer-related microbiome
composition. Finally, it must be highlighted that the in-
cluded studies were carried out in different geographical
areas (e.g., Europe, Asia, the USA), a feature that may in-
fluence the diversity of the intestinal microbiome [42].
The mode of subsistence and diet seem to be the most
important natural factors impacting the intestinal micro-
biome, and diet varies between ethnic groups, national-
ities, and people who live in rural or urban areas, with
the latter being especially enriched in Bacteroides, Bifi-
dobacterium, and Firmicutes [42].
The limited number of studies and the methodological
heterogeneity hampered any meta-analytic approach of
the present data and it should be carefully considered
when interpreting the available body of evidence.
Clinical impact and future perspectives
Although the evidence remains limited, the potential re-
lationship between intestinal microbiome composition
and outcomes of colorectal cancer surgery is a promising
field of research that may have compelling clinical rele-
vance. Indeed, despite the significant advances in surgi-
cal techniques and devices, colorectal cancer surgery is
still associated with a non-negligible morbidity and mor-
tality risk. Concerning AL in particular, the role of
microbiome composition may represent one missing
piece to explain the susceptibility of certain patients. In-
deed, detecting specific bacteria with a negative impact
on anastomotic healing could help the surgeon adapting
the surgical strategy (e.g., stoma vs. primary anasto-
mosis) to the individual patient’s risk level, also taking
into account the presence of an “unfavorable”
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microbiome. An experimental study of animal models has
already shown successful attempts to prevent AL by intro-
ducing oral phosphate and phosphate carrier compounds
after low colorectal anastomosis in the presence of patho-
gens expressing collagenase (Pseudomonas aeruginosa,
Serratia marcescens, and Enterococcus faecalis) [43].
Another appealing concept regarding the intestinal
microbiome is its possible use as a biomarker for the
diagnosis of colorectal cancer, as well as its predictor of
cancer aggressiveness, treatment outcomes, and even re-
sponse to therapy. All included studies focusing on
oncological outcomes suggested that specific bacteria
such as F. nucleatum or CAGs could be used as inde-
pendent predictors of survival, recurrence, and mortality
in colorectal cancer patients. As a high abundance of F.
nucleatum is associated with worse oncological out-
comes of surgery, its detection in tumoral tissues before
surgery could help to predict a more aggressive course
of the disease, therefore leading to possible strategic
changes in cancer treatment, such as more radical sur-
gery with lymph node debulking, closer surveillance in-
tervals for early recurrence detection, and even adjusted
chemotherapy regimens.
In light of these clinical perspectives, we performed a
quick search on ClinicalTrial.gov to identify pertinent on-
going clinical trials. We can report of two studies assessing
the relationship between microbiome and postoperative
complications (NCT04005118) or anastomotic leakage
(NCT03496441) in patients undergoing colorectal surgery.
Both studies are observation cohort studies; the first study
is ongoing whereas the second one appears to have com-
pleted the recruitment phase. Their results will substan-
tially contribute to elucidate the characteristics of the
intestinal microbiome in patients developing or not post-
operative complication after colorectal surgery and will
support further clinical and animal research in the field.
Indeed, it remains unclear whether microbiome compos-
ition is a cause or the result of clinical outcomes in colo-
rectal cancer patients and its characterization is so
complex and influenced by so many factors that will defin-
itely require multiple investigations [44–46].
Moreover, researchers should continue to study the
impact of preoperative ATB and MBP son intestinal
microbiome and subsequently on the short- and long-
term postoperative outcomes. Current evidence is still
inconclusive about the efficacy of prophylactic tech-
niques or preparations to avoid complications such as
AL [5]. Thus, there is an urgent need for research stud-
ies to analyze the microbiome composition in deep, to
elucidate the effects (potentially beneficial or harmful) of
different microbes on the processes of wound healing
and development of early postoperative complications
[5, 47]. Finally, research may advance looking for treat-
ments that may influence microbiome composition to
favor symbiotic and beneficial microbes that can con-
tribute to improve colorectal surgery outcomes.
Conclusions
The present systematic review demonstrates that the
current literature about the role of intestinal microbiome
on colorectal cancer surgery outcomes is limited. How-
ever, there is consistency in the available data supporting
a plausible linked between the intestinal microbiome
composition and the occurrence of postoperative com-
plications in colorectal cancer surgery patients. Further
investigations are awaited to assess this association and
elucidate whether intestinal microbiome characterization
could be used as a prognostic marker in colorectal can-
cer patients.
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